Skip to main content
AmigoFish

Jefferies London 2026: Generate Biomedicines' CEO Mike Nally describes the rationale behind a recent CAR-T deal with Anthropic, updates us on the company's TSLP, and more

From BiotechTV - News · · 10 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

He describes the win-win nature of working with Anthropic, which is related to redesigning CAR T-Cell Signaling. Plus, he discusses room for improvement in the TSLP space and why he believes Generate's candidate could be best in class.

Back to BiotechTV - News · Report a problem